STOCK TITAN
  1. Home
  2. Sec-filings
  3. SILO
  4. [Form 4] Silo Pharma, Inc. Insider Trading Activity

SILO Form 4: Silo Pharma CEO increases direct share ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Silo Pharma, Inc. insider share purchases reported

A reporting person serving as both a director and Chief Executive Officer of Silo Pharma, Inc. (SILO) filed a Form 4 disclosing open‑market purchases of the company’s common stock. On November 18, 2025, the insider purchased 7,500 shares at a weighted average price of $0.4033 per share. On November 19, 2025, the insider purchased an additional 4,500 shares at a weighted average price of $0.405 per share. Following these transactions, the insider directly owns 209,932 shares of Silo Pharma common stock.

Positive

  • None.

Negative

  • None.
Insider Weisblum Eric
Role Chief Executive Officer
Bought 12,000 shs ($5K)
Type Security Shares Price Value
Purchase Common Stock 4,500 $0.405 $2K
Purchase Common Stock 7,500 $0.4033 $3K
Holdings After Transaction: Common Stock — 209,932 shares (Direct)
Footnotes (1)
  1. This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 18, 2025 at prices ranging from $0.4000 to $0.4050. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 19, 2025 at prices ranging from $0.3975 to $0.4100. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Weisblum Eric
(Last) (First) (Middle)
C/O SILO PHARMA, INC.
677 N. WASHINGTON BOULEVARD
(Street)
SARASOTA FL 34236
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Silo Pharma, Inc. [ SILO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/18/2025 P 7,500 A $0.4033(1) 205,432 D
Common Stock 11/19/2025 P 4,500 A $0.405(2) 209,932 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 18, 2025 at prices ranging from $0.4000 to $0.4050. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
2. This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 19, 2025 at prices ranging from $0.3975 to $0.4100. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Eric Weisblum 11/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did Silo Pharma (SILO) disclose in this Form 4 filing?

The filing reports that a Silo Pharma, Inc. insider who is both a director and Chief Executive Officer purchased shares of the company’s common stock in the open market on two consecutive days in November 2025.

How many Silo Pharma (SILO) shares did the insider buy and at what prices?

The insider purchased 7,500 common shares on November 18, 2025 at a weighted average price of $0.4033 per share and 4,500 common shares on November 19, 2025 at a weighted average price of $0.405 per share.

How many Silo Pharma (SILO) shares does the insider own after these transactions?

After the reported transactions, the insider directly owns 209,932 shares of Silo Pharma common stock.

Were the Silo Pharma (SILO) insider purchases made in single trades or multiple trades?

The purchases on both November 18, 2025 and November 19, 2025 were executed in multiple transactions within intraday price ranges, with the reported prices representing weighted average prices.

What were the trading price ranges for the Silo Pharma (SILO) insider transactions?

On November 18, 2025, trades occurred between $0.4000 and $0.4050 per share. On November 19, 2025, trades occurred between $0.3975 and $0.4100 per share.

Is the insider filing for Silo Pharma (SILO) an individual or part of a group?

The Form 4 is indicated as being filed by one reporting person, not by more than one reporting person or a group.

What is the reporting person’s relationship to Silo Pharma (SILO)?

The reporting person is identified as a director and an officer, holding the title of Chief Executive Officer of Silo Pharma, Inc.